Current problems in cancer. Case reports最新文献_第8页

Rare case of epithelioid angiosarcoma presenting as nodular pulmonary opacities in a 23-year-old woman 一名 23 岁女性罕见的上皮样血管肉瘤结节性肺不张病例

Current problems in cancer. Case reports Pub Date : 2024-04-21 DOI: 10.1016/j.cpccr.2024.100290

Zein Kattih , Jonathan Moore , Alain Borczuk , Ann E. Tilley

引用次数: 0

Simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma: A case report 同时由 PTHrp 和降钙素三醇介导的高钙血症与肺腺癌可能自发转化为鳞癌有关：病例报告

Current problems in cancer. Case reports Pub Date : 2024-04-15 DOI: 10.1016/j.cpccr.2024.100289

Run Yu

{"title":"Simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma: A case report","authors":"Run Yu","doi":"10.1016/j.cpccr.2024.100289","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100289","url":null,"abstract":"<div><p>Hypercalcemia is a common paraneoplastic syndrome. Malignancies cause hypercalcemia by various mechanisms. Usually a single mechanism underlies paraneoplastic hypercalcemia. Two simultaneous mechanisms associated with one malignancy, however, are occasionally encountered. Here a rare case is reported to describe simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma. This 81-year-old male with history of resected lung adenocarcinoma developed hypercalcemia. The peak albumin-corrected calcium was 13.4 mg/dL (normal 8.6–10.4) with ionized calcium 1.70 mmol/L (normal 1.09–1.29). Laboratory tests showed PTH 7 pg/ml (normal 11–51), PTHrP 43.7 pmol/L (normal <2.3), 25-hydroxyvitamin D 33 ng/ml (normal 20–50), 1,25-dihydroxyvitamin D 71.0 pg/ml (19.9–79.3), TSH 3.1 µIU/mL (normal 0.3–4.7). CT showed new right lower lobe lung masses, paraesophageal and pericaval lymph nodes, and a cranial lesion. Biopsy of a lung mass revealed predominantly squamous cell carcinoma. He was treated with intravenous fluid and zoledronate with normalization of calcium levels. Vitamin D supplement was discontinued. The patient's clinical condition deteriorated before chemotherapy was started. He died shortly after comfort care was initiated. Pursuing multiple causes of paraneoplastic hypercalcemia is worthwhile as the treatment towards each mechanism is different.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"14 ","pages":"Article 100289"},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000127/pdfft?md5=cedc7f8438be9a1bb9c951b6b5166d87&pid=1-s2.0-S2666621924000127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140554082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges in managing chronic kidney disease with simultaneous renal transplant immunosuppressant induced buccal squamous cell carcinoma and gastric Burkitt's like lymphoma: A case report 同时患有肾移植免疫抑制剂诱发的口腔鳞状细胞癌和胃伯基特样淋巴瘤的慢性肾病患者的治疗挑战：病例报告

Current problems in cancer. Case reports Pub Date : 2024-04-04 DOI: 10.1016/j.cpccr.2024.100288

Syeda Sara Tajammul , Shruti Maheshwari , Javeria Munir , Khalil Al-Farsi , Ali Allawati , Zamzam Al Hashami , Layth Mula-Hussain

{"title":"Challenges in managing chronic kidney disease with simultaneous renal transplant immunosuppressant induced buccal squamous cell carcinoma and gastric Burkitt's like lymphoma: A case report","authors":"Syeda Sara Tajammul , Shruti Maheshwari , Javeria Munir , Khalil Al-Farsi , Ali Allawati , Zamzam Al Hashami , Layth Mula-Hussain","doi":"10.1016/j.cpccr.2024.100288","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100288","url":null,"abstract":"<div><p>Immunodeficiency is associated with higher cancer incidence, especially in transplanted patients; however, it is unknown whether there is a link between immunodeficiency and the development of multiple primary malignancies. Immunosuppressive drugs may either indirectly potentiate the effect of carcinogens or directly damage the DNA. Skin cancers are the most common malignancies diagnosed in renal transplant recipients. Management of immunosuppression in recipients of transplants who are living with cancer is complex and challenging. A concerted approach between transplant professionals, oncologists, and allied health professionals is therefore needed to ensure optimal care for transplant recipients who are developing immunodeficiency-induced malignancies. Here, we report a challenging case that presented with two simultaneous malignancies (buccal squamous cell carcinoma and gastric Burkitt's-like lymphoma) after nine years of being on immunosuppressants after the kidney transplant. The patient tolerated his cancer treatments with some grade II-III toxicities and is currently a two-year disease-free survivor. Focusing on the curative intent approaches for the two cancers with the adjustment of the immunosuppressant medications, besides the complications associated with these radical treatments, is worthy of being presented to the transplant and oncology teams globally.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"14 ","pages":"Article 100288"},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000115/pdfft?md5=848d60d4cfd716d236f3f30a83a3b20e&pid=1-s2.0-S2666621924000115-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140533884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Completed durable response of advanced endometrial cancer treated with pembrolizumab without surgical intervention or systemic chemotherapy: A case report 使用 pembrolizumab 治疗晚期子宫内膜癌，未进行手术干预或全身化疗，却完成了持久应答：病例报告

Current problems in cancer. Case reports Pub Date : 2024-03-17 DOI: 10.1016/j.cpccr.2024.100285

Anusha Adkoli , Rodrigo Alcorta Proaño , Eugenia Girda

{"title":"Completed durable response of advanced endometrial cancer treated with pembrolizumab without surgical intervention or systemic chemotherapy: A case report","authors":"Anusha Adkoli , Rodrigo Alcorta Proaño , Eugenia Girda","doi":"10.1016/j.cpccr.2024.100285","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100285","url":null,"abstract":"<div><p>Endometrial cancer remains the most common gynecologic malignancy in the United States. Novel molecular targets are being explored for treatment of advanced uterine. Molecular targets in signaling cascades have been identified including immune checkpoint inhibitors. This is a case of 63-year-old G0 with locally advanced unstaged undifferentiated/dedifferentiated TMB-H/MSI endometrial cancer, who had progression of disease after neoadjuvant radiation therapy. She was intolerant of systemic chemotherapy and declined surgical intervention but had subsequent complete response after 9 cycles of pembrolizumab. She has remained disease free for a total of 30 months (about 2.5 years) of follow up. Standard of care for advanced uterine cancer includes multimodality treatment with surgery, radiation, and systemic chemotherapy. This patient's response to treatment demonstrates that immunotherapy as an upfront treatment may be a reasonable alternative for patients with endometrial cancer with specific molecular profile regardless of histology.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"14 ","pages":"Article 100285"},"PeriodicalIF":0.0,"publicationDate":"2024-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000085/pdfft?md5=928435e2c6ff4093a59dd325e40539ab&pid=1-s2.0-S2666621924000085-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140181394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Merkel cell carcinoma of the breast: A case report 乳腺梅克尔细胞癌：病例报告

Current problems in cancer. Case reports Pub Date : 2024-03-16 DOI: 10.1016/j.cpccr.2024.100287

Catherine McNulty , Shabnam Mortazavi , Joseph Giessinger , Sepehr Hamidi

引用次数: 0

Detection of a co-mutation in the epidermal growth factor receptor gene exon 20 H773L/V774M by FoundationOne test and treatment with osimertinib: A case report 通过FoundationOne检测发现表皮生长因子受体基因第20外显子H773L/V774M的共突变，并接受奥希替尼治疗：病例报告

Current problems in cancer. Case reports Pub Date : 2024-03-08 DOI: 10.1016/j.cpccr.2024.100286

Hiroshi Yoshida , Hiroaki Ozasa , Kentaro Hashimoto , Yusuke Shima , Keiichiro Suminaga , Hitomi Ajimizu , Takashi Nomizo , Hironori Yoshida , Masahiro Yoshioka , Masashi Kanai , Takehito Shukuya , Manabu Muto , Toyohiro Hirai

{"title":"Detection of a co-mutation in the epidermal growth factor receptor gene exon 20 H773L/V774M by FoundationOne test and treatment with osimertinib: A case report","authors":"Hiroshi Yoshida , Hiroaki Ozasa , Kentaro Hashimoto , Yusuke Shima , Keiichiro Suminaga , Hitomi Ajimizu , Takashi Nomizo , Hironori Yoshida , Masahiro Yoshioka , Masashi Kanai , Takehito Shukuya , Manabu Muto , Toyohiro Hirai","doi":"10.1016/j.cpccr.2024.100286","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100286","url":null,"abstract":"<div><p>Among cases of non-small cell lung cancer (NSCLC) with EGFR mutations, NSCLC with deletions in EGFR exon 19 or 21 L858R account for 85 %. Frequency of NSCLC with minor mutations in EGFR is about 9 %, whilst EGFR exon 20 insertion mutation account for 6 % of the cases, determining it as a rare mutation. In this case, minor EGFR mutation and compound mutation EGFR H773L/V774M, were detected. Oncomine Dx target test (Oncomine), FoundationOne, and Amoy Dx polymerase chain reaction panel (Amoy 9-in-1 kit) were used as companion diagnostic tests. FoundationOne was the only one able to detect EGFR exon 20 H773L/V774M mutations. Drug therapy for NSCLC with compound mutations in EGFR exon 20 is not yet established. Unsuccessful treatments with EGFR-TKIs such as Erlotinib, Gefitinib, and Afatinib have been reported. There have also been reports of successful treatments with Osimertinib in combination with Bevacizumab. In the presented case, Osimertinib monotherapy was successful in treating NSCLC with EGFR exon 20 compound mutation. Osimertinib, therefore, has the potential to treat NSCLC with EGFR exon 20 H773L/V774M mutation, and can be a key drug for treating EGFR rare mutations.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"14 ","pages":"Article 100286"},"PeriodicalIF":0.0,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000097/pdfft?md5=747e780082018d7614de042efcf5d883&pid=1-s2.0-S2666621924000097-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140134053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma cfDNA in Carcinoma of unknown primary: A case series 血浆 cfDNA 在不明原发癌中的应用：一个病例系列

Current problems in cancer. Case reports Pub Date : 2024-02-10 DOI: 10.1016/j.cpccr.2024.100283

Rajat Thawani , Ajay Mohinani , Mason McLellan , Nima Nabavizadeh , Sean Goodyear , Adel Kardosh

引用次数: 0

Blue-ink tattoo reaction associated with immune checkpoint inhibitor treatment of metastatic colorectal cancer, a case report 与免疫检查点抑制剂治疗转移性结直肠癌相关的蓝墨水纹身反应，一份病例报告

Current problems in cancer. Case reports Pub Date : 2024-02-04 DOI: 10.1016/j.cpccr.2024.100281

Nolan Holley , Jessica Patterson , Michael Kolodney , Joanna Kolodney

{"title":"Blue-ink tattoo reaction associated with immune checkpoint inhibitor treatment of metastatic colorectal cancer, a case report","authors":"Nolan Holley , Jessica Patterson , Michael Kolodney , Joanna Kolodney","doi":"10.1016/j.cpccr.2024.100281","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100281","url":null,"abstract":"<div><p>Immune checkpoint inhibitors (ICIs) have revolutionized the field of oncology and transformed the management of many malignancies, especially for patients with metastatic disease. Dermatologic toxicities are among the most common immune-related adverse events (irAEs) of ICIs and can manifest in various ways. We report the case of a 56-year-old male with metastatic colorectal cancer treated with ipilimumab and nivolumab who then developed dermatologic abnormalities confined to the blue-ink regions of his long-standing multicolored tattoos on multiple areas of his body. The patient's reaction resolved after intralesional injection of triamcinolone acetonide. Tattoo reactions associated with ICI treatment are rare, and to our knowledge, there have been no published cases of dermatologic irAEs isolated to blue-pigmented areas of multicolored tattoos. It is of great importance to have awareness of the possibility of this type of reaction and to provide appropriate care for patients undergoing treatment with ICIs.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"13 ","pages":"Article 100281"},"PeriodicalIF":0.0,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000048/pdfft?md5=d5613591666210d0658f522c5ce12bbc&pid=1-s2.0-S2666621924000048-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139719195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short-term corticosteroid therapy consecutive to hemodialysis and charcoal hemoperfusion for methotrexate-induced acute kidney injury in an elderly lymphoma patient 一名老年淋巴瘤患者因甲氨蝶呤诱发急性肾损伤，在接受血液透析和炭化血液灌流治疗后连续接受短期皮质类固醇治疗

Current problems in cancer. Case reports Pub Date : 2024-02-03 DOI: 10.1016/j.cpccr.2024.100282

Misato Tane , Hiroki Hosoi , Hideki Kosako , Yukiko Yamano , Takayuki Hiroi , Shogo Murata , Toshiki Mushino , Shin-Ichi Araki , Takashi Sonoki

{"title":"Short-term corticosteroid therapy consecutive to hemodialysis and charcoal hemoperfusion for methotrexate-induced acute kidney injury in an elderly lymphoma patient","authors":"Misato Tane , Hiroki Hosoi , Hideki Kosako , Yukiko Yamano , Takayuki Hiroi , Shogo Murata , Toshiki Mushino , Shin-Ichi Araki , Takashi Sonoki","doi":"10.1016/j.cpccr.2024.100282","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100282","url":null,"abstract":"<div><p>Acute kidney injury (AKI) due to delayed methotrexate (MTX) elimination is a severe potential adverse event of high-dose (HD)-MTX treatment. However, no treatment for HD-MTX-induced AKI has been established. In addition, there are no reports of corticosteroids being administered for HD-MTX-induced AKI. Here, we report the case of a 77-year-old male with central nervous system lymphoma, who developed an AKI after the second course of HD-MTX. He underwent charcoal hemoperfusion and hemodialysis immediately after the development of the AKI. He also received short-term corticosteroid therapy due to inflammatory findings and a positive drug-induced lymphocyte stimulation test for MTX. Our case suggests that short-term corticosteroid therapy consecutive to hemodialysis and charcoal hemoperfusion may be useful for AKI induced by delayed MTX elimination even in the elderly.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"13 ","pages":"Article 100282"},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266662192400005X/pdfft?md5=080e6d8d893f78355246fce604eb8a27&pid=1-s2.0-S266662192400005X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139714561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms 一例具有组织学转化和多重耐药机制的表皮生长因子受体突变肺癌 IV 期疑难病例

Current problems in cancer. Case reports Pub Date : 2024-02-02 DOI: 10.1016/j.cpccr.2024.100284

Joel Rivera-Concepcion , Ying-Chun Lo , Dipesh Uprety , Alex A. Adjei , Vinicius Ernani , Konstantinos Leventakos

引用次数: 0